Lantheus (NASDAQ:LNTH) Sets New 52-Week High on Analyst Upgrade

Lantheus Holdings, Inc. (NASDAQ:LNTH) hit a new 52-week high on Wednesday after Truist Financial raised their price target on the stock from $96.00 to $141.00. Truist Financial currently has a buy rating on the stock. Lantheus traded as high as $100.80 and last traded at $96.00, with a volume of 860140 shares traded. The stock had previously closed at $77.70.

A number of other research firms have also recently commented on LNTH. JMP Securities upped their target price on Lantheus from $100.00 to $130.00 and gave the company an “outperform” rating in a research note on Wednesday. Mizuho upped their target price on Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, May 3rd. B. Riley upped their target price on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research note on Thursday, April 18th. SVB Leerink boosted their price target on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Thursday. Finally, StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a report on Friday, May 3rd. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $113.86.

Insider Activity

In other news, CAO Andrea Sabens sold 341 shares of the stock in a transaction on Monday, May 13th. The stock was sold at an average price of $76.89, for a total transaction of $26,219.49. Following the completion of the sale, the chief accounting officer now owns 62,898 shares in the company, valued at approximately $4,836,227.22. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $76.89, for a total value of $26,219.49. Following the transaction, the chief accounting officer now directly owns 62,898 shares of the company’s stock, valued at approximately $4,836,227.22. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Heinz Christoph Maeusli sold 18,373 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $79.19, for a total value of $1,454,957.87. Following the completion of the transaction, the director now directly owns 23,340 shares in the company, valued at $1,848,294.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,269 shares of company stock worth $2,557,300. Insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Lantheus

Several hedge funds have recently made changes to their positions in the company. Moody National Bank Trust Division grew its position in Lantheus by 1.1% during the 2nd quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock worth $1,203,000 after purchasing an additional 162 shares during the period. Shaker Investments LLC OH grew its position in Lantheus by 0.7% during the 1st quarter. Shaker Investments LLC OH now owns 27,962 shares of the medical equipment provider’s stock worth $1,740,000 after purchasing an additional 182 shares during the period. NBC Securities Inc. boosted its stake in shares of Lantheus by 28.4% during the 1st quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider’s stock worth $53,000 after acquiring an additional 191 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 208 shares in the last quarter. Finally, Retirement Systems of Alabama boosted its stake in shares of Lantheus by 0.3% during the 1st quarter. Retirement Systems of Alabama now owns 86,005 shares of the medical equipment provider’s stock worth $5,353,000 after acquiring an additional 226 shares in the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Stock Performance

The firm’s 50 day moving average price is $81.01 and its 200-day moving average price is $67.35. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.55 and a current ratio of 4.84. The firm has a market capitalization of $8.57 billion, a PE ratio of 18.87 and a beta of 0.51.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.11. The business had revenue of $369.98 million for the quarter, compared to analyst estimates of $349.46 million. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. On average, research analysts expect that Lantheus Holdings, Inc. will post 6.46 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.